8279.Two
The company operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
Business. The company operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating a low reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 2.2, suggesting the company has sufficient short-term assets to cover its short-term liabilities. The price-to-book ratio of 1.1 and price-to-tangible-book ratio of 1.1 indicate that the company's market value is closely aligned with its book value, suggesting a relatively stable valuation.
In terms of profitability, the company demonstrates a return on equity (ROE) of 11.44% and a return on assets (ROA) of 8.91%, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and asset base, which is favorable compared to industry norms.
The company's revenue is primarily concentrated in a single geographic region, as disclosed in its financial segments. While the exact breakdown of revenue by segment is not provided, the company's exposure to a single market may increase its vulnerability to regional economic fluctuations. The absence of detailed segment data limits the ability to assess diversification risks comprehensively.
The company's growth trajectory is supported by a strong operating cash flow of 319,483,000 and a free cash flow of 193,853,000, which provides flexibility for reinvestment and shareholder returns. The capital expenditure of -63,564,000 indicates a reduction in capital spending, which may reflect a strategic shift or a focus on optimizing existing assets. The outlook for the current fiscal year suggests continued operational efficiency and potential for revenue growth.
The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk, with no significant dilution potential identified. The key risk flag of negative net cash after subtracting total debt highlights the need for careful liquidity management. The valuation adjustments applied in the custom valuations suggest a conservative approach to asset valuation, which may impact the company's market perception.
Recent events, including financial filings and transcripts, have not revealed any material changes in the company's operations or strategic direction. The company's financial health remains stable, with no significant adverse developments reported in the latest disclosures. The absence of recent events does not indicate a lack of activity but rather a consistent and predictable operational performance.
- The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.1.
- Strong profitability metrics, including a return on equity of 11.44% and a return on assets of 8.91%, indicate efficient capital utilization.
- The company's liquidity position is characterized as medium, with a current ratio of 2.2.
- The company's growth trajectory is supported by a strong operating cash flow and a reduction in capital spending.
- The company faces a medium liquidity risk and a low dilution risk, with no significant dilution potential identified.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 8279.TWO Market data — financials · 2026-05-27